ArticleJournal of internal medicine2022
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
Article in Journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis.Molecular biomedicine · 2026Article
- Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Clinical and molecular links between chronic systemic inflammation and structural damage in axial spondyloarthritis.Arthritis research & therapy · 2025Article
- Article
- Expression and significance ofBiomarkers in medicine · 2025Article
- Molecular insights into the relationship between sustained CRP elevation and endothelial dysfunction in axial spondyloarthritis.RMD open · 2025Article
- Proteomics by qPCR Using the Proximity Extension Assay (PEA).Methods in molecular biology (Clifton, N.J.) · 2025Article
- Monitoring Cerebrospinal Fluid Inflammatory Mediators by Olink Target 48 Cytokine Panel.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting.JAAD international · 2024Article
- Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience.Life (Basel, Switzerland) · 2024Article
- Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast.Frontiers in immunology · 2024Review
- Association between psoriasis and serum apolipoprotein A1 and B: A systematic review and meta-analysis.Heliyon · 2023Review
- Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets.Frontiers in immunology · 2023Article
- Fatty Acid-Binding Proteins in Psoriasis-A Review.Metabolites · 2022Review
- The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.Journal of internal medicine · 2022Article
- Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.Frontiers in immunology · 2022Review
- Psoriasis and cardiovascular risk: associated and protective factors.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives(1) To evaluate clinical and molecular cardiovascular disease (CVD) signs and their relationship with psoriatic arthritis (PsA) features and (2) to identify a clinical patient profile susceptible to benefit from methotrexate (MTX) and/or apremilast regarding CVD risk.
methodsThis cross-sectional study included 100 patients with PsA and 100 age-matched healthy donors. In addition, an exploratory cohort of 45 biologically naïve patients treated for 6 months with apremilast, MTX or combined therapy according to routine clinical practice was recruited. Extensive clinical and metabolic profiles were obtained. Ninety-nine surrogate CVD-related molecules were analysed in plasma and peripheral blood mononuclear cells (PBMCs). Hard cluster analysis was performed to identify the clinical and molecular phenotypes. Mechanistic studies were performed on adipocytes.
resultsCardiometabolic comorbidities were associated with disease activity and long-term inflammatory status. Thirty-five CVD-related proteins were altered in the plasma and PBMCs of PsA patients and were associated with the key clinical features of the disease. Plasma levels of some of the CVD-related molecules might distinguish insulin-resistant patients (MMP-3, CD163, FABP-4), high disease activity (GAL-3 and FABP-4) and poor therapy outcomes (CD-163, LTBR and CNTN-1). Hard cluster analysis identified two phenotypes of patients according to the rates of cardiometabolic comorbidities with distinctive clinical and molecular responses to each treatment.
conclusions(1) Novel CVD-related proteins associated with clinical features could be emerging therapeutic targets in the context of PsA and (2) the pleiotropic action of apremilast could make it an excellent choice for the management of PsA patients with high CVD risk, targeting metabolic alterations and CVD-related molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.